Obs&Gyn: Gyn malignancies Flashcards
Cervical screening programme
- 25-49 years: 3-yearly screening
- 50-64 years: 5-yearly screening
*cervical screening cannot be offered to women over 64
Cervical screening in pregnancy
Cervical screening in pregnancy is usually delayed until 3 months post-partum unless missed screening or previous abnormal smears
Possible results of the cervical screen
Grades of CIN
CIN is a precancerous lesion. They are graded histologically as:
- CIN 1 – 1/3 thickness affected (can revert to normal in 10-23 months)
- CIN 2 – 2/3 thickness
- CIN 3 – Full thickness (carcinoma in situ)
Management of Cervical Intraepithelial Neoplasia (CIN)
- Cold coagulation in CIN 1
- Follow up according to NHS cervical screening
guidelines
•LLETZ (Large Loop Excision of Transformation zone → performed mostly under local anaesthesia
to confirm diagnosis and treat)
HPV vaccine
Gardasil → protects against HPV 6, 11, 16 & 18
- all 12- and 13-year-olds (girls AND boys) in school Year 8 will be offered the human papillomavirus (HPV) vaccine
- given as 2 doses - girls have the second dose between 6-24 months after the first, depending on local policy
- HPV vaccination should also be offered to men who have sex with men under the age of 45 to protect against anal, throat and penile cancers
Common subtypes of HPV that are linked to a disease
- 6 & 11: causes genital warts
- 16 & 18: linked to a variety of cancers, most notably cervical cancer
Risk factors predisposing to cervical cancer
- HPV serotypes 16,18 & 33
- smoking
- HIV
- early first intercourse, many sexual partners
- high parity
- lower socioeconomic status
- combined oral contraceptive pill
Symptoms of cervical cancer
- Intermenstrual bleeding/post- coital bleeding
- Vaginal discharge
- Pelvic pain (advanced disease)
- Abnormal looking cervix
- Pelvic vein thrombosis causing a swollen leg
Types of cervical cancer
- Squamous cell carcinoma (85%)
- Adenocarcinoma
- Rare forms: malignant melanoma, sarcoma
Investigations in cervical cancer
- Colposcopy – cervical biopsy
- Cystoscopy and sigmoidoscopy
- Bloods: FBC, U&E, LFTs
- MRI pelvis, CT abdomen and Chest
- Clinical staging :FIGO
- Cone biopsy
Management of cervical cancer
- Wertheim’s Hysterectomy/ aka radical hysterectomy
- Radiotherapy
Risk factors for endometrial cancer
- obesity
- nulliparity
- early menarche
- late menopause
- unopposed oestrogen (addition of a progestogen to oestrogen reduces this risk)
- diabetes mellitus
- tamoxifen
- polycystic ovarian syndrome
- hereditary non-polyposis colorectal carcinoma
Symptoms of endometrial cancer
- postmenopausal bleeding is the classic symptom
- premenopausal women may have a change intermenstrual bleeding
- pain and discharge are unusual features
Ix in endometrial cancer
- Ultrasound (endometrial thickness)
- Hysteroscopy / Dilatation & Curettage
- MRI of abdomen and pelvis
- Chest X ray
- Bloods-FBC,U&E and LFT
Who should we investigate for endometrial cancer?
- women >= 55 years who present with postmenopausal bleeding should be referred using the suspected cancer pathway
- first-line investigation is trans-vaginal ultrasound - a normal endometrial thickness (< 4 mm) has a high negative predictive value
- hysteroscopy with endometrial biopsy
Management of endometrial cancer
- localised disease is treated with total abdominal hysterectomy with bilateral salpingo-oophorectomy
- Patients with high-risk disease may have post-operative radiotherapy
- progestogen therapy is sometimes used in frail elderly women not consider suitable for surgery
Risk factors for ovarian cancer
- family history: mutations of the BRCA1 or the BRCA2 gene or HPNCC
- many ovulations: early menarche, late menopause, nulliparity